Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Pluvia who wrote (1705)	2/12/1999 2:35:00 PM
From: ztect	Respond to of 2135

Hey Pluvia....You didn't answer any of my questions.... Here the questions are again...could you PLEASE make an effort to answer these this time....I'd really appreciate your valuable insights... Plus do you have any background or access to resources in medical training? And if you do, what are these qualifications and / or resources? Thanks in advance for answering my questions THIS TIME. Sincerely, ztect =========== Per release... "...Lehman Brothers analyst, Dr. Eric Ende, said favorable results for the two drugs have only been seen in mice and not in people, making it far too early to bank on EntreMed's discoveries..." Don't they have to test it on mice before they can test it on people? Ende's statement seems like maybe just a very justifiably cautious one, though not necessarily a derisive one. What "phase" exactly is the drug in, do you know? Has there been any experimental unpublicized (for liability reasons) use of this drug that anyone knows about? What is the plan for clinical testing? Plus does this company's product only work on certain types of cancer? Since a cancer cell isn't a cancer cell isn't a cancer cell, the just asked question seems pretty critical when accessing "the competition". For example, lung cancer (I believe which involves "oat cells".....md's help!!! clear up any of my mistakes) presents and metastasizes at different rates than the cell types for pancreatic, ovarian, or stomach cancers.....thus there made be a need for a variety of products to combat different cancerous types of tumors .... Don't you think this is, at least, a possibility? z

To: Pluvia who wrote (1705)	2/12/1999 2:37:00 PM
From: Bear Down	Read Replies (2) \| Respond to of 2135

It seems that although the cancer tumors haven't shown shrinkage, investors account balances have !!!!! It is amazing that this stock traded higher after Bristol Myers pulled their financing. How can ENMD possibly fund a study or any further research without the funding allocated by Bristol Myers? ENMD<------------ strong sell, target 10